<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02020876</url>
  </required_header>
  <id_info>
    <org_study_id>CU001</org_study_id>
    <nct_id>NCT02020876</nct_id>
  </id_info>
  <brief_title>Decision Impact Study to Measure the Influence of DECIPHER on Treatment Recommendations</brief_title>
  <acronym>DECIDE</acronym>
  <official_title>GenomeDx Decipher Test for Metastatic Disease in Prostate Cancer for Patients With Adverse Pathology Post Radical Prostatectomy: Does it Impact Physician Decision Making?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GenomeDx Biosciences Corp</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GenomeDx Biosciences Corp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical utility study pilot is based on a review of real but de-identified and&#xD;
      randomized patient cases and aims to evaluate Urologists' treatment recommendations before&#xD;
      and after reviewing the results provided by the Decipher test. This is a pilot study and the&#xD;
      primary intent is to help guide development and design of future clinical utility studies for&#xD;
      Decipher&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary and secondary objectives will be assessed in retrospectively selected prostate&#xD;
      cancer patients treated with radical prostatectomy with one or more adverse pathological&#xD;
      features (APFs)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in treatment recommendation</measure>
    <time_frame>1.5 years</time_frame>
    <description>To determine the extent to which the use of the Decipher test influences treatment recommendations by physicians post radical prostatectomy (RP).&#xD;
This decision impact study aims to evaluate Urologists' treatment recommendations before and after reviewing the results provided by the Decipher test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urologist's perception regarding the utility of the Decipher</measure>
    <time_frame>1.5 years</time_frame>
    <description>Changes in Urologists expressed level of confidence in the treatment recommendation as measured by the response to item 4a in the eCRF survey.&#xD;
Urologist's perception regarding the utility of the Decipher test as measured by the responses to question 4b and 38b and 38c in the eCRF survey.&#xD;
Agreement in treatment recommendation</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">21</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Practicing urologic surgeons</arm_group_label>
    <description>Performing at least 60 radical prostate surgeries annually</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DECIPHER Questionnaire</intervention_name>
    <description>Participants are asked to complete a questionnaire to assess the impact of Decipher on physicians' treatment recommendation. All participants use the same data collection instrument. Each participant opinion is collected based on a random selection of cases.</description>
    <arm_group_label>Practicing urologic surgeons</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This is an exploratory study utilizing archived tumor specimens and demographic and&#xD;
        pathologic characteristics derived from the patient's medical charts. The study&#xD;
        participants are the urologists who review the selected case files.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Criteria (Participant enrollment)&#xD;
&#xD;
        Inclusion Criteria Study participants:&#xD;
&#xD;
          1. Practicing board-certified urologic surgeons&#xD;
&#xD;
          2. Performing at least 40 radical prostate surgeries annually&#xD;
&#xD;
        Exclusion Criteria Study Participants:&#xD;
&#xD;
        (1) Did not meet the inclusion criteria&#xD;
&#xD;
        Criteria (Case selection)&#xD;
&#xD;
        Inclusion Criteria Case File:&#xD;
&#xD;
        Patient cases eligible for this study were treated with radical prostatectomy and have one&#xD;
        or more adverse pathological features present defined as:&#xD;
&#xD;
        Pathological Gleason score &gt;= 8 or Gleason score 7 with primary pattern 4; Pathological&#xD;
        stage T3A (= Extraprostatic extension) or T3B (=Seminal vesicle invasion); Positive&#xD;
        surgical margins Gleason grade upgrade from biopsy to surgery&#xD;
&#xD;
        Exclusion Criteria Case File:&#xD;
&#xD;
        Metastatic disease (M+) prior to surgery Received any neo-adjuvant prostate cancer&#xD;
        treatment with radical prostatectomy (radiation, hormone, chemotherapy)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elai Davicioni, pHd</last_name>
    <role>Principal Investigator</role>
    <affiliation>GenomeDx Biosciences Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Badani Ketan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Urology, Columbia University, New York, NY USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GenomeDx Bioscience Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Badani K, Thompson DJ, Buerki C, Davicioni E, Garrison J, Ghadessi M, Mitra AP, Wood PJ, Hornberger J. Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group. Oncotarget. 2013 Apr;4(4):600-9.</citation>
    <PMID>23592338</PMID>
  </results_reference>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>December 18, 2013</study_first_submitted>
  <study_first_submitted_qc>December 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2013</study_first_posted>
  <last_update_submitted>December 19, 2013</last_update_submitted>
  <last_update_submitted_qc>December 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

